期刊文献+

肿瘤患者血清血管内皮生长因子检测意义 被引量:3

Serum Vascular endothelial growth factors dection and its Clinic significance in tumour patients
暂未订购
导出
摘要 目的研究血管内皮生长因子(VEGF)与肿瘤的细胞学分型、细胞分化程度及其与肿瘤发生、转归、预后的相关性。方法采用ELISA法,用SLT酶标扫描仪扫描计算结果,数据分析采用SPSS 11.0统计软件。结果多种肿瘤患者体内高表达VEGF,其表达水平与肿瘤细胞的分化程度有关(P<0.01),但与细胞学分型无相关性;患者血清VEGF含量改变与肿瘤的转归及预后有显著的相关性(P<0.01)。结论检测患者血清VEGF水平对判断肿瘤的发生、转归、预后及研究细胞分化程度具有重要价值,同时有助于指导临床合理使用抗血管新生治疗。 Objective To study the relation ship between Vascular endothelial growth factors and cytologic subtype,differentiated degree of turnout cells as well as tumour oceurrer/ce, outcome and prognosis, the VEGF level was measureel with VEGF-EI,ISA kit, data had analyzed with SPSS11.0 Stat. Software. Methods Most turnout patients express high level VEGF, and it a signiticaut relativity with differentiated degree of tumour cells( P 〈 0.01 ) ,but no relativity with cytologic subtype; The change of VEGF level had a signiticaut relativity with occurrence,outcome and prognosis of tumour( P 〈 0. 01).Conclusion VEGF is useful in had the occurrence ,outcome and prognosis of tumour as well as studying the differentiated degree of tumour cells. It can guide the correct antiangiogenic therapies.
出处 《中国临床保健杂志》 CAS 2006年第1期14-16,共3页 Chinese Journal of Clinical Healthcare
基金 安徽省优秀青年科技基金(20020318)
关键词 血管内皮生长因子类 肿瘤形成过程 新生血管化 病理性 Vascular endothelial growth factors Neoplastic processes Neovascularizafion, Pathologic
  • 相关文献

参考文献7

  • 1[1]Lee A,Dubli E,Bobrow L,et al.Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis[ J].J Pathol,1998,185(4):394-401.
  • 2[2]Linderholm B,Tavelin B,Grankvist K,et al.Does vascular endothelial growth factor (VEGF)predict local relapse and survival in radiotherapy-treated node-negative breast cancer?[ J].Br J Cancer,1999,81 (4):727-732.
  • 3孟冬娅,胡晓芳,高洪福,薛文成.检测血清VEGF、CEA、TSGF在肿瘤中的临床意义[J].中国现代医学杂志,2004,14(1):117-118. 被引量:19
  • 4[4]Ferrara N,Hillan K,Gerber H,et al.Discovery and outcome of bevacizumab,an anti-VEGF antibody for treating cancer[J].Nat Rev Drug Discov,2004,3(5):391-400.
  • 5[5]Johnson D,Fehrenbacher L,Novotny W,et al.Randomized phase Ⅱ trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer[J].J Clin Oncol,2004,22(11):2184-2191.
  • 6[6]Rugo HS.Bevacizumab in the treatment of breast cancer:rationale and current data[J].Oncologist,2004,1(suppl 9):43-49.
  • 7[7]Rini B,Halabi S,Taylor J,et al.Cancer and Leukemia Group B 90206:a randomized phase Ⅲ trial of interferon-alpha or interferon alpha plus anti-vascular endothelial growth factor antibody(bevacizumab) in metastatic renal cell carcinoma[ J ].Clin Cancer Res,2004,10(8):2584-2586.

二级参考文献4

共引文献18

同被引文献35

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部